Abbvie Inc (ABBV)

$167.76

+1.19

(+0.71%)▲

Market is closed - opens 8 PM, 21 Nov 2024
star icon

AbbVie Inc develops and sells prescription drugs in various therapeutic areas, including immunology, oncology, and virology

Performance

  • $165.74
    $167.86
    $167.76
    downward going graph

    1.2%

    Downside

    Day's Volatility :1.26%

    Upside

    0.06%

    downward going graph
  • $137.65
    $207.32
    $167.76
    downward going graph

    17.95%

    Downside

    52 Weeks Volatility :33.61%

    Upside

    19.08%

    downward going graph

Returns

PeriodAbbvie IncSector (Health Care)S&P500
3 Months
-14.64%
-7.6%
5.3%
6 Months
2.96%
-2.3%
11.2%
1 Year
20.93%
10.1%
30.4%
3 Years
45.06%
7.5%
26.0%

Highlights

Market Capitalization
294.4B
Book Value
$3.41
Dividend Share
6.2
Dividend Yield
3.94%
Earnings Per Share (EPS)
2.87
PE Ratio
58.04
PEG Ratio
0.4
Wall Street Target Price
204.735
Profit Margin
9.22%
Operating Margin TTM
28.93%
Return On Assets TTM
7.72%
Return On Equity TTM
56.41%
Revenue TTM
55.5B
Revenue Per Share TTM
31.4
Quarterly Revenue Growth YOY
3.8%
Gross Profit TTM
41.5B
EBITDA
25.6B
Diluted Eps TTM
2.87
Quarterly Earnings Growth YOY
-0.12
EPS Estimate Current Year
10.94
EPS Estimate Next Year
12.15
EPS Estimate Current Quarter
2.91
EPS Estimate Next Quarter
2.95

Analyst Recommendation

Buy
    65%Buy
    34%Hold
    0
    0%Sell
Based on 35 Wall street analysts offering stock ratings for Abbvie Inc(by analysts ranked 0 to 5 stars)
Based on 35 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
23
23
22
Hold
12
12
13
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 22.04%

Current $167.76
Target $204.74

Company Financials

FY18Y/Y Change
Revenue
32.8B
↑ 16.08%
Net Income
5.7B
↑ 7.12%
Net Profit Margin
17.36%
↓ 1.46%
FY19Y/Y Change
Revenue
33.3B
↑ 1.57%
Net Income
7.9B
↑ 38.6%
Net Profit Margin
23.69%
↑ 6.33%
FY20Y/Y Change
Revenue
45.8B
↑ 37.69%
Net Income
4.6B
↓ 41.44%
Net Profit Margin
10.08%
↓ 13.61%
FY21Y/Y Change
Revenue
56.2B
↑ 22.69%
Net Income
11.5B
↑ 150.04%
Net Profit Margin
20.54%
↑ 10.46%
FY22Y/Y Change
Revenue
58.1B
↑ 3.3%
Net Income
11.8B
↑ 2.55%
Net Profit Margin
20.39%
↓ 0.15%
FY23Y/Y Change
Revenue
54.3B
↓ 6.44%
Net Income
4.9B
↓ 58.91%
Net Profit Margin
8.95%
↓ 11.44%
Q2 FY23Q/Q Change
Revenue
13.9B
↑ 13.42%
Net Income
2.0B
↑ 746.86%
Net Profit Margin
14.6%
↑ 12.64%
Q3 FY23Q/Q Change
Revenue
13.9B
↑ 0.45%
Net Income
1.8B
↓ 12.15%
Net Profit Margin
12.77%
↓ 1.83%
Q4 FY23Q/Q Change
Revenue
14.3B
↑ 2.69%
Net Income
822.0M
↓ 53.77%
Net Profit Margin
5.75%
↓ 7.02%
Q1 FY24Q/Q Change
Revenue
12.3B
↓ 13.92%
Net Income
1.4B
↑ 66.55%
Net Profit Margin
11.12%
↑ 5.37%
Q2 FY24Q/Q Change
Revenue
14.5B
↑ 17.48%
Net Income
1.4B
↑ 0.07%
Net Profit Margin
9.47%
↓ 1.65%
Q3 FY24Q/Q Change
Revenue
14.5B
↓ 0.01%
Net Income
1.6B
↑ 13.94%
Net Profit Margin
10.8%
↑ 1.33%
FY18Y/Y Change
Total Assets
59.4B
↓ 16.15%
Total Liabilities
67.8B
↑ 3.21%
FY19Y/Y Change
Total Assets
89.1B
↑ 50.15%
Total Liabilities
97.3B
↑ 43.5%
FY20Y/Y Change
Total Assets
150.6B
↑ 68.96%
Total Liabilities
137.5B
↑ 41.3%
FY21Y/Y Change
Total Assets
146.5B
↓ 2.68%
Total Liabilities
131.1B
↓ 4.64%
FY22Y/Y Change
Total Assets
138.8B
↓ 5.27%
Total Liabilities
121.5B
↓ 7.3%
FY23Y/Y Change
Total Assets
134.7B
↓ 2.95%
Total Liabilities
124.3B
↑ 2.3%
Q2 FY23Q/Q Change
Total Assets
135.4B
↑ 0.61%
Total Liabilities
122.5B
↑ 1.01%
Q3 FY23Q/Q Change
Total Assets
136.2B
↑ 0.63%
Total Liabilities
124.1B
↑ 1.33%
Q4 FY23Q/Q Change
Total Assets
134.7B
↓ 1.11%
Total Liabilities
124.3B
↑ 0.18%
Q1 FY24Q/Q Change
Total Assets
148.9B
↑ 10.51%
Total Liabilities
140.8B
↑ 13.28%
Q2 FY24Q/Q Change
Total Assets
141.9B
↓ 4.66%
Total Liabilities
135.1B
↓ 4.06%
Q3 FY24Q/Q Change
Total Assets
143.4B
↑ 1.05%
Total Liabilities
137.4B
↑ 1.65%
FY18Y/Y Change
Operating Cash Flow
13.4B
↑ 34.81%
Investing Cash Flow
-1.0B
↑ 267.15%
Financing Cash Flow
-14.4B
↑ 161.18%
FY19Y/Y Change
Operating Cash Flow
13.3B
↓ 0.77%
Investing Cash Flow
596.0M
↓ 159.24%
Financing Cash Flow
18.7B
↓ 229.95%
FY20Y/Y Change
Operating Cash Flow
17.6B
↑ 32.0%
Investing Cash Flow
-37.6B
↓ 6401.51%
Financing Cash Flow
-11.5B
↓ 161.48%
FY21Y/Y Change
Operating Cash Flow
22.8B
↑ 29.5%
Investing Cash Flow
-2.3B
↓ 93.76%
Financing Cash Flow
-19.0B
↑ 65.54%
FY22Y/Y Change
Operating Cash Flow
24.9B
↑ 9.51%
Investing Cash Flow
-623.0M
↓ 73.42%
Financing Cash Flow
-24.8B
↑ 30.27%
FY23Y/Y Change
Operating Cash Flow
22.8B
↓ 8.44%
Investing Cash Flow
-2.0B
↑ 222.47%
Financing Cash Flow
-17.2B
↓ 30.56%
Q2 FY23Q/Q Change
Operating Cash Flow
6.3B
↑ 50.7%
Investing Cash Flow
-341.0M
↓ 31.66%
Financing Cash Flow
-3.9B
↓ 36.69%
Q3 FY23Q/Q Change
Operating Cash Flow
7.6B
↑ 19.86%
Investing Cash Flow
-369.0M
↑ 8.21%
Financing Cash Flow
-2.7B
↓ 32.12%
Q4 FY23Q/Q Change
Operating Cash Flow
4.8B
↓ 37.25%
Investing Cash Flow
-800.0M
↑ 116.8%
Financing Cash Flow
-4.4B
↑ 67.19%
Q1 FY24Q/Q Change
Operating Cash Flow
4.0B
↓ 15.0%
Investing Cash Flow
-9.6B
↑ 1098.5%
Financing Cash Flow
10.8B
↓ 343.18%

Technicals Summary

Sell

Neutral

Buy

Abbvie Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abbvie Inc
Abbvie Inc
-10.07%
2.96%
20.93%
45.06%
93.9%
Eli Lilly And Company
Eli Lilly And Company
-16.85%
-6.2%
27.14%
189.28%
556.57%
Johnson & Johnson
Johnson & Johnson
-5.97%
1.24%
1.32%
-4.13%
12.22%
Merck & Co. Inc.
Merck & Co. Inc.
-9.22%
-25.48%
-4.67%
19.35%
14.02%
Novo Nordisk A/s
Novo Nordisk A/s
-10.28%
-22.11%
2.42%
89.28%
289.6%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abbvie Inc
Abbvie Inc
57.94
58.04
0.4
10.94
0.56
0.08
0.04
3.41
Eli Lilly And Company
Eli Lilly And Company
78.72
78.72
0.69
13.16
0.65
0.14
0.01
15.83
Johnson & Johnson
Johnson & Johnson
25.45
25.45
0.92
9.96
0.21
0.08
0.03
29.14
Merck & Co. Inc.
Merck & Co. Inc.
20.2
20.2
0.07
7.74
0.28
0.11
0.03
17.58
Novo Nordisk A/s
Novo Nordisk A/s
34.03
34.03
1.53
22.7
0.89
0.21
0.01
27.07
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abbvie Inc
Abbvie Inc
Buy
$293.8B
93.9%
57.94
9.22%
Eli Lilly And Company
Eli Lilly And Company
Buy
$692.7B
556.57%
78.72
20.48%
Johnson & Johnson
Johnson & Johnson
Buy
$370.8B
12.22%
25.45
16.74%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$244.3B
14.02%
20.2
19.23%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$472.8B
289.6%
34.03
35.01%

Insights on Abbvie Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 14.46B → 14.46B (in $), with an average decrease of 0.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, 822.0M → 1.56B (in $), with an average increase of 17.4% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 27.1% return, outperforming this stock by 6.2%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 189.0% return, outperforming this stock by 144.7%

Institutional Holdings

  • Vanguard Group Inc

    9.71%

  • BlackRock Inc

    7.72%

  • State Street Corp

    4.40%

  • Morgan Stanley - Brokerage Accounts

    4.22%

  • JPMorgan Chase & Co

    3.03%

  • Capital Research & Mgmt Co - Division 3

    2.08%

Corporate Announcements

  • Abbvie Inc Dividends March,2025

    In the quarter ending March,2025. Abbvie Inc has declared dividend of $1.64

    Read More

Company Information

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Organization
Abbvie Inc
Employees
50000
CEO
Mr. Richard A. Gonzalez
Industry
Health Technology

FAQs